Light Mode
$5.93 ↑ +0.00 (+0.03%) Trading Up from the previous close of $5.93, $0.15 below the day’s high of $6.08
-27.73 (-81.90%) / 6M
Momentum, market sentiment, and recent alerts
CAPR reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +0.0%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMDâ€), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.